



Feticide for Fetal congenital malformation: a case presentation

Dr Odriy P Mukombwe Dr C. Verenga



Outline



- Introduction
- History
- Discussion
- Summary



Introduction




- Myelomeningocele is the commonest neural tube defect (Bowman, 2024)
- Caused by failure of primary neurulation
- Incidence is highly variable (<1-7 per 1000 live births) (Blencowe, 2018)
- Incidence depend on ethnicity, geography and nutritional factors
- In Africa, prevalence quoted pooled burden of 32.95/10,000 births, highest in East Africa with 111.13/10,000 (Zaganjor, 2016)







- 9513 pregnancies
- 176 fetuses with defects
- Total defects=340
- Incidence 2 per 100






FMU CENTRAL NERVOUS SYSTEM



CENTRAL NERVOUS SYSTEM (N=59)









- Mrs. PFM, waitress, married
- 36 year old, P2G3
- Referred @ 32 weeks + 2 days
- No personal or family history of fetal abnormalities.
- Presented in FMU @ 34 weeks for a 2nd opinion scan
- 2 children at home alive and well

- No preconception visit
- Preconception folate not taken
- Planned pregnancy
- First trimester scan done: NT 1.4 mm, nasal bone present, CRL 39.4mm;
- No biochemical tests done
- BS to BSOB ratio not done at T1 scan.
- Booked @ 16 weeks
- No fetal anomaly scan done
- TORCH screen not done





Examination


BMI 28kg/m2
CVS, RS, CNS –
unremarkable
Abdomen- HOF 34cm,
cephalic, longitudinal
lie and regular fetal
heart rate






Sacrococcygeal defect









Ultrasound exam



Cervical region
Crowding of
posterior fossa
Arnold Chiari
malformation






Ventriculomegaly and posterior fossa









Lemon head and orbits













Ultrasound-extremities











Extremities













 36 year old P2G3 referred in third trimester with fetus with sacrococcygeal myelomeningocele and secondary severe ventriculomegaly.



Discussion-Risk factors



- Genetics
- Folic acid deficiency
- supplementation reduces risk by 62% (Wakoya, 2023)
- folic acid antagonists increase risk (Hernández-Díaz S, 2000)
- concentrations low in mothers carrying fetus with NTD (van der Put, 2001)
- Age >35 [OR 3.54 (95% CI 1.67-7.47)] (Wakoya, 2023)
- Poorly controlled diabetes mellitus (Guerin, 2007)
- BMI >30kg/m2 increase risk by twofold (Racusin, 2012)



Prenatal diagnosis



Ultrasound

- TVS
- Detect >90% anencephaly, 80% encephalocele but low for spina bifida (44-54%) (Maruotti, 2016)
- TAS @ 18-20 weeks
- detect 92-95% of spina bifida, 100% anencephaly (Cameron, 2009)

MAFP

- @ 16-18 weeks ≥2.0 or 2.5 MoM
- Sensitivity 75.1%, specificity 97.7%, FPR 2.2% (Wang, 2009)
- Results influenced by age, weight and type 1 DM
- Also raised in abdominal wall defects, multiple pregnancies







- Counselling on
- 1. Condition
- 2. Complications of condition
- 3. Fetal interventions
- 4. Postnatal care
- 5. Prognosis

- Almost all patients with myelomeningocele have Chiari II malformation, most have hydrocephalus
- major cognitive deficits
- brainstem dysfunction
- Severe neurologic deficits- complete paralysis, absence of sensation
- bladder and bowel affected in 97% of patients
- Hydrocephalus lower among sacral lesions
- Long-term complications –learning difficulties, seizures, orthopedic problems, pressure ulcers







 Termination or fetal demise occur in 60-70% of pregnancies with NTDs (Johnson, 2012)

Fetal surgery inclusion criteria

- Open spina bifida with upper boundary between T1 and S1
- Hindbrain herniation
- Gestational age 19+0 to 25+6 weeks of gestation at time of procedure
- Maternal characteristics age ≥18 years
- understands requirements and able to consent
- counselled on other options





Outcomes of fetal surgery

Results in:

- -Decreased need for shunting (RR 0.53, 95% CI 0.41-0.67)
- -Improved motor development and function
- -Similar cognitive outcomes
- -Possible improvement in bladder function (RR 0.74, 95% CI 0.48-1.12)
- -Modest improvement in QoL and impact on family

The Management of Myelomeningocele Study: full cohort 30-month pediatric outcomes

Diana L Farmer ¹, Elizabeth A Thom ¹, John W

Brock III ¹, Pamela K Burrows ¹, Mark P Johnson ¹,

Lori J Howell ¹, Jody A Farrell ¹, Nalin Gupta ¹, N

Scott Adzick ¹; Management of Myelomeningocele

Study Investigators ¹





Randomized Controlled Trial

Prenatal Repair and Physical Functioning Among Children With Myelomeningocele: A Secondary Analysis of a Randomized Clinical Trial

Amy J Houtrow et al. JAMA Pediatr. 2021.







- Preterm birth -46% in MOMS trial vs 5%
- Chorioamnionitis
- Chorion separation
- Spontaneous membrane rupture
- Oligohydramnios
- Placental abruption
- Maternal bleeding
- Need for caesarean section







- Level of myelomeningocele
- thoracic and high lumbar have higher mortality and greater disability
- Severity of Chiari II malformation
- degree of hindbrain herniation
- Presence or absence of hydrocephalus
- Motor deficits
- assess for positional abnormalities at rest and with activity







- Serial ultrasound examination
- Nonstress tests and BPP from 34 weeks due to risk of stillbirth
- Delivery at center with level 3 or more neonatal
- Mode of delivery
- Postnatal surgery within
 72 hours of delivery

- Fetocide
- Our patient
- Bad prognostic markers
- Hydrocephalus
- Advanced gestational age







- Injection of a pharmacologic agent into a fetus or amniotic fluid to cause fetal asystole
- Done for pregnancies beyond 21 weeks + 6 days (RCOG)
- First introduced in 1990s in abortion care
- Discussed with reference to uncertainty within the medical profession about the legal status of a live birth following TOP.

- To avoid resuscitation dilemma for pregnant woman, nurses and doctors.
- To avoid medicolegal and economic consequences of an unintended live birth that survives.
- To shorten the mean induction-abortion interval.
- To soften fetal tissues, may ease evacuation and decrease procedure time and minimize risk of complications.
- Respect the choice of the woman who prefer to know fetal heart stopped prior to evacuation.





Choice of agent

• Digoxin	Potassium chloride	Lignocaine
 Img Intra-amniotic/ intracardiac/ intra- umbilical Not immediately effective Done 1-2 days prior to abortion 	 Intracardiac/intraumbili cal Immediately effective 	 10-20ml of 2% Primary or secondary agent intracardiac./intraumb ilical/intraamniotic/intrathoracic Effective within 2 mins Can repeat dose 20-40 mins later









Role of professional discretion. Issue of professional vulnerability.

Legal uncertainty and variation in professional practice.

Life and death at the edge of viability in pregnancy/ neonatal care.

Little existing empirical work, lack of theoretically driven analysis.

Little knowledge about how participation is conceptualized or experienced by those closely involved - parents and health

- Substantial body of literature on technical/clinical aspects of feticide as a procedure
- Broader issue of fetal killing as a social trend
- Available literature as a medical procedure suggest more informed understanding of its context but falls short of a systematic analysis of that context.
- Literature centered around TOP for fetal abnormality.







- After counselling chose fetocide
- Intracardiac KCL achieved asystole in 3 mins
- Drainage of ventricles done –reduced HC to below 40mm
- IOL with oral misoprostol
- Postdelivery counselling





Thank you

Odriy P Mukombwe opmukombwe87@gmail.com